Category: GLOBE-NEWSWIRE

FLUX INVESTOR NEWS: Flux Power Holdings, Inc. Investors that Suffered Losses are Encouraged to Contact RLF About Ongoing Investigation into the Company (NASDAQ: FLUX)

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) — Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Flux Power Holdings, Inc. (NASDAQ: FLUX) resulting from allegations that Flux Power may have issued materially misleading business information to the investing public. So What: If […]

Read More

LNW INVESTOR NEWS: Light & Wonder, Inc. Investors that Suffered Losses are Encouraged to Contact RLF About Ongoing Investigation into the Company (Nasdaq: LNW)

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) — Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Light & Wonder, Inc. (NASDAQ: LNW) for potential violations of the federal securities laws. So What: If you purchased Light & Wonder securities you may […]

Read More

V INVESTOR NEWS: Visa Inc. Investors that Suffered Losses are Encouraged to Contact RLF About Ongoing Investigation into the Company (NYSE: V)

NEW YORK, Oct. 21, 2024 (GLOBE NEWSWIRE) — Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Visa Inc. (NYSE: V) resulting from allegations that Visa may have issued materially misleading business information to the investing public. So What: If you purchased Visa […]

Read More

Leil Storage: Green File Storage for Africa

Leil Storage for Africa TALLINN, Estonia, Oct. 21, 2024 (GLOBE NEWSWIRE) — In alignment with Africa Human Rights Day, Leil Storage announces the expansion of its Green Storage Initiative, an endeavor set to revolutionize file storage across Africa. This initiative underscores commitment to sustainability and affordability, promising a profound impact on the continent’s digital infrastructure. […]

Read More

Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset

The agreement gives Angelini Pharma an option to exclusive licensing rights to develop and commercialize CV-011, a clinical Phase 1 investigational novel compound with broad potential to treat brain health diseases Cureverse receives undisclosed upfront payments and is eligible for future milestone-dependent payments and royalties, while retaining rights to commercialize CV-01 in the Republic of […]

Read More